Breaking News Instant updates and real-time market news.

AZRX

AzurRx BioPharma

$1.25

-0.23 (-15.54%)

16:06
07/08/19
07/08
16:06
07/08/19
16:06

AzurRx BioPharma begins Initiation of phase 2 clinical study for MS1819-SD

AzurRx BioPharma announced that it has initiated a Phase 2 clinical trial to investigate MS1819-SD in combination with standard porcine enzyme replacement therapy for patients with cystic fibrosis that suffer from severe exocrine pancreatic insufficiency, but continue to experience clinical symptoms of fat malabsorption despite taking the maximum daily dose of PERTs. The digestive standard of care for both CF and chronic pancreatitis patients with EPI are commercially-available PERTs. Ideally, a stable daily dose of PERT will enable CF patients to eat a normal to high-fat diet and minimize unpleasant gastrointestinal symptoms. In practice, however, a substantial number of CF patients do not achieve normal absorption of fat with PERTs. Achieving an optimal nutritional status, including normal fat absorption levels, in CF patients is important for maintaining better pulmonary function, physical performance and prolonging survival. Furthermore, a decline of body mass index around the age of 18 years predicts a substantial drop in lung function.

AZRX AzurRx BioPharma
$1.25

-0.23 (-15.54%)

01/25/19
ROTH
01/25/19
INITIATION
Target $10.5
ROTH
Buy
AzurRx BioPharma initiated with a Buy at Roth Capital
Roth Capital analyst Jerry Isaacson initiated AzurRx BioPharma with a Buy rating and $10.50 price target. In a research note to investors, Isaacson says he assumes MS1819 to treat EPI in CF patients will be approved for the patient population in 2022, and says his model includes pricing starting at $18,000 per patient per year, in line with currently approved PERTs. MS1819 has numerous potential advantages over currently approved treatments, including reduced pill burden, and the fact that it is not derived from an animal source, he adds.
01/25/19
01/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. SS&C (SSNC) initiated with a Buy at Buckingham. 2. Capital Southwest (CSWC) initiated with a Neutral at B. Riley FBR. 3. Natural Gas Services (NGS) initiated with a Buy at Maxim. 4. Aptose Biosciences (APTO) initiated with an Outperform at Oppenheimer. 5. AzurRx BioPharma (AZRX) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/14/19
MAXM
02/14/19
INITIATION
Target $5
MAXM
Buy
AzurRx BioPharma initiated with a Buy at Maxim
Maxim analyst Caroline Palomeque initiated AzurRx BioPharma with a Buy rating and a price target of $5. The analyst cites the company's prioritizing of MS1819-SD development in Cystic Fibrosis given the "relatively undifferentiated" Pancreatic Enzyme Replacement Therapy market, stating the drug would be the "first non-porcine product available for exocrine pancreatic insufficiency that lowers pill burden, reduces risk of allergic reaction and improves quality of life".
06/11/19
NATL
06/11/19
INITIATION
Target $9
NATL
Buy
AzurRx BioPharma initiated with a Buy at National Securities
National Securities analyst Jonathan Aschoff initiated AzurRx BioPharma with a Buy rating and $9 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.